BAseLine TEstosterone as a Prognostic and/or Predictive bioMARKer in mHSPC

Summary

Despite large amounts of basic-science data supporting a role for androgens in PCa pathogenesis, there are conflicting clinical data on the role of endogenous testosterone in human de novo PCa pathogenesis. The investigators hypothesize that lower baseline serum testosterone is significantly associated with worse clinical outcomes in mHSPC patients undergoing continuous medical castration

Conditions

• Prostate Cancer Metastatic

Interventions

DIAGNOSTIC_TEST

Testosterone levels

Blood sample to determine testosterone levels

Sponsors & Collaborators

• Hospital Universitario Reina Sofia de Cordoba

  collaborator OTHER_GOV

• Hospitales Universitarios Virgen del Rocío

  collaborator OTHER

• Hospital Universitario Torrecárdenas

  collaborator OTHER

• Hospital Neurotraumatologico de Jaen

  collaborator OTHER

• Hospital San Carlos, Madrid

  collaborator OTHER

• Institut Mutualiste Montsouris

  collaborator OTHER

• San Raffaele University Hospital, Italy

  collaborator OTHER

• Azienda Ospedaliera San Giovanni Battista

  collaborator OTHER

• Chinese University of Hong Kong

  collaborator OTHER

• Medical University Innsbruck

  collaborator OTHER

• University of Padova

  collaborator OTHER

• UMC Utrecht

  collaborator OTHER

• Ignacio Puche Sanz

  lead OTHER

Principal Investigators

• Ignacio Puche · Fundación para la Investigación Biosanitaria de Andalucía Oriental (FIBAO)

Eligibility

Min Age

18 Years

Max Age

89 Years

Sex

MALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2023-01-01

Primary Completion

2025-01-01

Completion

2026-01-01

Countries

• Spain

Study Locations